Microscopic polyangiitis
Drug research and approvals for microscopic polyangiitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 10 studies of microscopic polyangiitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 3 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 10
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 0
- Ocular Manifestations of Granulomatosis With Polyangiitis.NCT07664709 · Not reported · Military Institute od Medicine National Research Institute · starts Mar 1, 2024
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesNCT07087912 · Phase 4 · University of Sao Paulo General Hospital · starts Mar 16, 2026
- Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)NCT06983821 · Phase 3 · Ottawa Hospital Research Institute · starts Nov 10, 2025
- Special Drug Use-results Survey for Long-term Use(Avacopan)NCT06758271 · Not reported · Kissei Pharmaceutical Co., Ltd. · starts Jul 29, 2022
- Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisNCT06611696 · Phase 4 · Chiba University · starts Nov 15, 2024
- Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic…NCT03290456 · Not applicable · Hospices Civils de Lyon · starts Aug 20, 2019
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)NCT03004326 · Not reported · Peter Merkel · starts Jan 1, 2017
- VCRC Tissue RepositoryNCT02967068 · Not reported · University of Pennsylvania · starts Nov 1, 2016
- Vasculitis Pregnancy RegistryNCT02593565 · Not reported · University of Pennsylvania · starts Nov 1, 2015
Approved 2
Phase 3 4
- AzathioprineAmidophosphoribosyltransferase inhibitor
- CyclophosphamideDNA inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- PrednisoneGlucocorticoid receptor agonist
Phase 2 4
- VilobelimabComplement C5 inhibitor
- InfliximabTNF-alpha inhibitor
- BlisibimodTumor necrosis factor ligand superfamily member 13B inhibitor
- Prednylidene
How its trials ended
54 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 15 whose ending is known, 33% met their primary endpoint, 20% missed it and 47% stopped early.
- Completed, result not reported2037%
- Ongoing1120%
- Status unknown815%
- Met its primary endpoint59%
- Missed its primary endpoint36%
- Stopped: other or unclear36%
- Stopped: funding24%
- Stopped: enrollment or feasibility12%
- Stopped: sponsor or business decision12%
| Oct 7, 2021 | TavneosAs an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis… | ChemoCentryx, Inc. | Approved |
| Sep 27, 2019 | RituxanRITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with… | Genentech, Inc. | Approved |
| Apr 19, 2011 | RituxanFor the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and… | Genentech, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA